The Globe and Mail reports in its Tuesday, Feb. 2, edition that Raymond James analyst Rahul Sarugaser commenced coverage of Opsens with an "outperform" recommendation. The Globe's David Leeder writes in the Eye On Equities column that Mr. Sarugaser targets the shares at $2.50. Analysts on average target the shares at $2.31. Mr. Sarugaser says in a note: "We believe Opsens's share of the rapidly expanding FRR/dPR market is beginning to grow, so, after a long period of relatively slow growth, we expect to see sales escalating materially during the next 4-6 quarters. We see further upside optionality in Opsens's new cardiology applications -- specifically, in TAVR -- and in its medical device and industrial partnerships."
© 2021 Canjex Publishing Ltd. All rights reserved.